Arrowhead Pharmaceuticals receives FDA clearance to begin phase 2/3 study of ARO-AAT
Arrowhead Pharma announced it has received clearance from the FDA to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNAi therapeutic for AATD. April 15, 2019